Faculty List

Katharina Lueckerath

Email Address: klueckerath@mednet.ucla.edu

Work Phone Number: 3102061146

Work Address:
650 Charles E Young Drive S
Los Angeles, CA 90095

Department / Division Affiliations
Adjunct Assistant Professor, Molecular & Medical Pharmacology

Research Interests

Dr. Katharina Lückerath’s research focuses on theranostic concepts with the goal to deliver new insights into tumor biology and its relationship and relevance to functional imaging and biomarker-driven treatments in nuclear medicine. Specifically, her research aims at elucidating mechanisms underlying failure of radioligand therapy - a type of targeted, systemic radiotherapy - in prostate- and pancreatic cancer. These mechanisms include, for example, tumor cell intrinsic resistance mechanisms, tumor protection by microenvironmental factors (immunosuppression, stroma), and suboptimal tumor radiation dose delivery. Poor understanding of these mechanisms represents a key barrier to the development of more effective radioligand therapy approaches. To improve radioligand therapy outcomes and to establish rationally chosen, translatable radioligand therapy-based combination therapies, the group characterizes cancer mouse models and patient samples, and uses diverse in vitroex vivo and in vivo analyses to identify targetable radioligand therapy-induced cell signaling alterations in tumor, stroma and immune cells that mitigate the effects of RLT. 


A selected list of publications:

Current Kyle, Meyer Catherine, Magyar Clara E, Mona Christine E, Almajano Joel, Slavik Roger, Stuparu Andreea D, Cheng Chloe, Dawson David W, Radu Caius G, Czernin Johannes, Lueckerath Katharina   Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity Clinical cancer research : an official journal of the American Association for Cancer Research, 2020; .
Stuparu Andreea D, Meyer Catherine A L, Evans-Axelsson Susan L, Lückerath Katharina, Wei Liu H, Kim Woosuk, Poddar Soumya, Mona Christine E, Dahlbom Magnus, Girgis Mark D, Radu Caius G, Czernin Johannes, Slavik Roger   Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study Theranostics, 2020; 10(6): 2612-2620.
Lapa Constantin, Lückerath Katharina, Kircher Stefan, Hänscheid Heribert, Grigoleit Götz U, Rosenwald Andreas, Stolzenburg Antje, Kropf Saskia, Einsele Hermann, Wester Hans-Jürgen, Buck Andreas K, Kortüm Klaus M, Schirbel Andreas   Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy British journal of haematology, 2019; 184(3): 440-443.
Lückerath Katharina, Wei Liu, Fendler Wolfgang P, Evans-Axelsson Susan, Stuparu Andreea D, Slavik Roger, Mona Christine E, Calais Jeremie, Rettig Matthew, Reiter Robert E, Herrmann Ken, Radu Caius G, Czernin Johannes, Eiber Matthias   Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer EJNMMI research, 2018; 8(1): 96.
Lückerath Katharina, Stuparu Andreea D, Wei Liu, Kim Woosuk, Radu Caius G, Mona Christine E, Calais Jeremie, Rettig Matthew, Reiter Robert E, Czernin Johannes, Slavik Roger, Herrmann Ken, Eiber Matthias, Fendler Wolfgang P   Detection Threshold and Reproducibility of Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018; 59(9): 1392-1397.
Stolzenburg Antje, Lückerath Katharina, Samnick Samuel, Speer Martin, Kneer Katharina, Schmid Jan-Stefan, Grigoleit Götz Ulrich, Hofmann Susanne, Beer Ambros J, Bunjes Donald, Knop Stefan, Buck Andreas K, Einsele Hermann, Lapa Constantin   Prognostic value of [ European journal of nuclear medicine and molecular imaging, 2018; 45(10): 1694-1704.
Lapa Constantin, Schreder Martin, Lückerath Katharina, Samnick Samuel, Rudelius Martina, Buck Andreas K, Kortüm Klaus M, Einsele Hermann, Rosenwald Andreas, Knop Stefan   [ British journal of haematology, 2018; 181(5): 701-703.
Lapa Constantin, Herrmann Ken, Schirbel Andreas, Hänscheid Heribert, Lückerath Katharina, Schottelius Margret, Kircher Malte, Werner Rudolf A, Schreder Martin, Samnick Samuel, Kropf Saskia, Knop Stefan, Buck Andreas K, Einsele Hermann, Wester Hans-Juergen, Kortüm K Martin   CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma Theranostics, 2017; 7(6): 1589-1597.
Buck Andreas K, Stolzenburg Antje, Hänscheid Heribert, Schirbel Andreas, Lückerath Katharina, Schottelius Margret, Wester Hans-Jürgen, Lapa Constantin   Chemokine receptor - Directed imaging and therapy Methods (San Diego, Calif.), 2017; 130(11): 63-71.
Fendler Wolfgang P, Stuparu Andreea D, Evans-Axelsson Susan, Lückerath Katharina, Wei Liu, Kim Woosuk, Poddar Soumya, Said Jonathan, Radu Caius G, Eiber Matthias, Czernin Johannes, Slavik Roger, Herrmann Ken   Establishing Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017; 58(11): 1786-1792.
Lapa Constantin, Kircher Stefan, Schirbel Andreas, Rosenwald Andreas, Kropf Saskia, Pelzer Theo, Walles Thorsten, Buck Andreas K, Weber Wolfgang A, Wester Hans-Juergen, Herrmann Ken, Lückerath Katharina   Targeting CXCR4 with [ Oncotarget, 2017; 8(57): 96732-96737.
Lapa Constantin, Schreder Martin, Schirbel Andreas, Samnick Samuel, Kortüm Klaus Martin, Herrmann Ken, Kropf Saskia, Einsele Herrmann, Buck Andreas K, Wester Hans-Jürgen, Knop Stefan, Lückerath Katharina   [ Theranostics, 2017; 7(1): 205-212.
Lapa Constantin, Schirbel Andreas, Samnick Samuel, Lückerath Katharina, Kortüm K Martin, Knop Stefan, Wester Hans-Jürgen, Buck Andreas K, Schreder Martin   The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma European journal of nuclear medicine and molecular imaging, 2017; 44(6): 1097-1098.
Fecher David, Hofmann Elisabeth, Buck Andreas, Bundschuh Ralph, Nietzer Sarah, Dandekar Gudrun, Walles Thorsten, Walles Heike, Lückerath Katharina, Steinke Maria   Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging PloS one, 2016; 11(8): e0160282.
Werner Rudolf A, Beykan Seval, Higuchi Takahiro, Lückerath Katharina, Weich Alexander, Scheurlen Michael, Bluemel Christina, Herrmann Ken, Buck Andreas K, Lassmann Michael, Lapa Constantin, Hänscheid Heribert   The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy Oncotarget, 2016; 7(27): 41233-41241.
Werner R A, Lückerath K, Schmid J S, Higuchi T, Kreissl M C, Grelle I, Reiners C, Buck A K, Lapa C   Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience Scientific reports, 2016; 6(27): 28081.
Lapa Constantin, Hänscheid Heribert, Wild Vanessa, Pelzer Theo, Schirbel Andreas, Werner Rudolf A, Droll Sabine, Herrmann Ken, Buck Andreas K, Lückerath Katharina   Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy Oncotarget, 2016; 7(15): 20033-40.
Lapa Constantin, Lückerath Katharina, Kleinlein Irene, Monoranu Camelia Maria, Linsenmann Thomas, Kessler Almuth F, Rudelius Martina, Kropf Saskia, Buck Andreas K, Ernestus Ralf-Ingo, Wester Hans-Jürgen, Löhr Mario, Herrmann Ken   (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma Theranostics, 2016; 6(3): 428-34.
Lapa Constantin, Knop Stefan, Schreder Martin, Rudelius Martina, Knott Markus, Jörg Gerhard, Samnick Samuel, Herrmann Ken, Buck Andreas K, Einsele Hermann, Lückerath Katharina   11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement Theranostics, 2016; 6(2): 254-61.
Herrmann Ken, Schottelius Margret, Lapa Constantin, Osl Theresa, Poschenrieder Andreas, Hänscheid Heribert, Lückerath Katharina, Schreder Martin, Bluemel Christina, Knott Markus, Keller Ulrich, Schirbel Andreas, Samnick Samuel, Lassmann Michael, Kropf Saskia, Buck Andreas K, Einsele Hermann, Wester Hans-Juergen, Knop Stefan   First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016; 57(2): 248-51.
Lapa Constantin, Lückerath Katharina, Rudelius Martina, Schmid Jan-Stefan, Schoene Alexander, Schirbel Andreas, Samnick Samuel, Pelzer Theo, Buck Andreas K, Kropf Saskia, Wester Hans-Jürgen, Herrmann Ken   [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience Oncotarget, 2016; 7(8): 9288-95.
Werner R A, Schmid J S, Muegge D O, Lückerath K, Higuchi T, Hänscheid H, Grelle I, Reiners C, Herrmann K, Buck A K, Lapa C   Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment Medicine, 2015; 94(45): e2016.
Lückerath Katharina, Lapa Constantin, Albert Christa, Herrmann Ken, Jörg Gerhard, Samnick Samuel, Einsele Herrmann, Knop Stefan, Buck Andreas K   11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma Oncotarget, 2015; 6(10): 8418-29.
Philipp-Abbrederis Kathrin, Herrmann Ken, Knop Stefan, Schottelius Margret, Eiber Matthias, Lückerath Katharina, Pietschmann Elke, Habringer Stefan, Gerngroß Carlos, Franke Katharina, Rudelius Martina, Schirbel Andreas, Lapa Constantin, Schwamborn Kristina, Steidle Sabine, Hartmann Elena, Rosenwald Andreas, Kropf Saskia, Beer Ambros J, Peschel Christian, Einsele Hermann, Buck Andreas K, Schwaiger Markus, Götze Katharina, Wester Hans-Jürgen, Keller Ulrich   In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma EMBO molecular medicine, 2015; 7(4): 477-87.
Lapa Constantin, Linsenmann Thomas, Lückerath Katharina, Samnick Samuel, Herrmann Ken, Stoffer Carolin, Ernestus Ralf-Ingo, Buck Andreas K, Löhr Mario, Monoranu Camelia-Maria   Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? PloS one, 2015; 10(3): e0122269.
Lapa Constantin, Knop Stefan, Lückerath Katharina   FDG PET/CT depicts cutaneous plasmocytoma Clinical nuclear medicine, 2014; 39(10): 910-1.
Lapa Constantin, Lückerath Katharina, Malzahn Uwe, Samnick Samuel, Einsele Herrmann, Buck Andreas K, Herrmann Ken, Knop Stefan   18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation Oncotarget, 2014; 5(17): 7381-91.
Lapa Constantin, Werner Rudolf A, Bluemel Christina, Lückerath Katharina, Schirbel Andreas, Strate Alexander, Buck Andreas K, Herrmann Ken   Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy EJNMMI research, 2014; 4(11): 46.
Lapa Constantin, Werner Rudolf A, Bluemel Christina, Lueckerath Katharina, Muegge Dirk O, Strate Alexander, Haenscheid Heribert, Schirbel Andreas, Allen-Auerbach Martin S, Bundschuh Ralph A, Buck Andreas K, Herrmann Ken   Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy EJNMMI research, 2014; 4: 74.
Lückerath Katharina, Lapa Constantin, Spahmann Annika, Jörg Gerhard, Samnick Samuel, Rosenwald Andreas, Einsele Herrmann, Knop Stefan, Buck Andreas K   Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology PloS one, 2013; 8(12): e84840.
Lückerath Katharina, Kirkin Vladimir, Melzer Inga Maria, Thalheimer Frederic B, Siele Dagmar, Milani Wiebke, Adler Thure, Aguilar-Pimentel Antonio, Horsch Marion, Michel Geert, Beckers Johannes, Busch Dirk H, Ollert Markus, Gailus-Durner Valerie, Fuchs Helmut, Hrabe de Angelis Martin, Staal Frank J T, Rajalingam Krishnaraj, Hueber Anne-Odile, Strobl Lothar J, Zimber-Strobl Ursula, Zörnig Martin   Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain Blood, 2011; 117(2): 519-29.
Guardiola-Serrano F, Rossin A, Cahuzac N, Lückerath K, Melzer I, Mailfert S, Marguet D, Zörnig M, Hueber A-O   Palmitoylation of human FasL modulates its cell death-inducing function Cell death & disease, 2010; 1(2): e88.
Vladimirova Valentina, Waha Andreas, Lückerath Katharina, Pesheva Penka, Probstmeier Rainer   Runx2 is expressed in human glioma cells and mediates the expression of galectin-3 Journal of neuroscience research, 2008; 86(11): 2450-61.
Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Lückerath K, Friedmann E, Novac N, Wels W S, Martoglio B, Hueber A-O, Zörnig M   The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells Cell death and differentiation, 2007; 14(9): 1678-87.